Ullrich WÃ¼llner

List of Publications by Year
in descending order

190 papers	10,813 citations	30070 54 h-index	37204 96 g-index
209 all docs	209 docs citations	209 times ranked	13417 citing authors

#	Article	IF	Citations
1	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 905-916.	2.8	7
2	Magnetic Resonance Imagingâ€“Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12. Movement Disorders, 2022, 37, 872-873.	3.9	5
3	Spatial and temporal immunoreaction of nestin, CD44, collagen IX and GFAP in human retinal MÃ¼ller cells in the developing fetal eye. Experimental Eye Research, 2022, 217, 108958.	2.6	4
4	The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3. Movement Disorders, 2022, 37, 1098-1099.	3.9	0
5	Epigenome-Wide Analysis of DNA Methylation in Parkinsonâ€™s Disease Cortex. Life, 2022, 12, 502.	2.4	14
6	Life style and Parkinsonâ€™s disease. Journal of Neural Transmission, 2022, 129, 1235-1245.	2.8	8
7	Methylation of alpha-synuclein in a Sudanese cohort. Parkinsonism and Related Disorders, 2022, 101, 6-8.	2.2	7
8	Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor. Movement Disorders, 2022, 37, 1924-1929.	3.9	6
9	Elevated serum mitochondrial DNA in females and lack of altered platelet mitochondrial methylation in patients with ParkinsonÂ´s disease. International Journal of Neuroscience, 2021, 131, 279-282.	1.6	13
10	Wound Healing of Descemet Membrane After Penetrating Keratoplasty and Its Relevance for Descemet Membrane Endothelial Keratoplasty Surgeons. Cornea, 2021, 40, 910-913.	1.7	3
11	Much ado about nothing? Off-target amplification can lead to false-positive bacterial brain microbiome detection in healthy and Parkinsonâ€™s disease individuals. Microbiome, 2021, 9, 75.	11.1	31
12	Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinsonâ€™s disease. Cell Reports, 2021, 34, 108807.	6.4	77
13	Abnormal subpopulations of monocytes in the cerebrospinal fluid of patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 84, 144-145.	2.2	6
14	Response to â€œBAP1 Germline Mutation Associated with Bilateral Primary Uveal Melanomaâ€• Ocular Oncology and Pathology, 2021, 7, 1-2.	1.0	0
15	Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinsonâ€™s Disease. Biology, 2021, 10, 716.	2.8	4
16	The patientsâ€™ perspective on the burden of idiopathic intracranial hypertension. Journal of Headache and Pain, 2021, 22, 67.	6.0	15
17	Epigenetic and gene expression changes of neuronal cells from MSA patients are pronounced in enzymes for cell metabolism and calcium-regulated protein kinases. Acta Neuropathologica, 2021, 142, 781-783.	7.7	1
18	PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPARÎ³â€“DNMT1 Interactions in the Genome. Cancers, 2021, 13, 3993.	3.7	2

#	Article	IF	Citations
19	Lesions of the cerebello-thalamic tract rather than the ventral intermediate nucleus determine the outcome of focused ultrasound therapy in essential tremor: A 3T and 7T MRIâ€“study. Parkinsonism and Related Disorders, 2021, 91, 105-108.	2.2	9
20	Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen. Scientific Reports, 2021, 11, 19857.	3.3	1
21	Multidisciplinary management to optimize outcome of ultrasound-guided high-intensity focused ultrasound (HIFU) in patients with uterine fibroids. Scientific Reports, 2021, 11, 22768.	3.3	7
22	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
23	Resting-state fMRI reveals increased functional connectivity in the cerebellum but decreased functional connectivity of the caudate nucleus in Parkinsonâ€™s disease. Neurological Research, 2020, 42, 62-67.	1.3	14
24	Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation. Ocular Oncology and Pathology, 2020, 6, 107-114.	1.0	5
25	Histological Corneal Alterations in Keratoconus After Crosslinkingâ€”Expansion of Findings. Cornea, 2020, 39, 333-341.	1.7	10
26	A pilot study of magnetic resonance fingerprinting in Parkinson's disease. NMR in Biomedicine, 2020, 33, e4389.	2.8	10
27	Cerebrospinal Fluid Levels of Kininogenâ€1 Indicate Early Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2020, 35, 2101-2106.	3.9	16
28	Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease. Redox Biology, 2020, 34, 101546.	9.0	66
29	MRI follow-up after magnetic resonance-guided focused ultrasound for non-invasive thalamotomy: the neuroradiologistâ€™s perspective. Neuroradiology, 2020, 62, 1111-1122.	2.2	21
30	Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3910.	4.1	20
31	Genome organization in proximity to the BAP1 locus appears to play a pivotal role in a variety of cancers. Cancer Science, 2020, 111, 1385-1391.	3.9	9
32	Melanocytoma of the Conjunctiva: Clinicopathologic Features of Three Cases. Ocular Oncology and Pathology, 2019, 5, 290-297.	1.0	4
33	Mutational Landscape of the BAP1 Locus Reveals an Intrinsic Control to Regulate the miRNA Network and the Binding of Protein Complexes in Uveal Melanoma. Cancers, 2019, 11, 1600.	3.7	30
34	Pyogenic granuloma associated with conjunctival epithelial neoplasia: report of nine cases. British Journal of Ophthalmology, 2019, 103, 1469-1474.	3.9	11
35	Polypharmacy in Parkinsonâ€™s disease: risks and benefits with little evidence. Journal of Neural Transmission, 2019, 126, 871-878.	2.8	17
36	Î±-Synuclein in Parkinsonâ€™s disease: causal or bystander?. Journal of Neural Transmission, 2019, 126, 815-840.	2.8	88

#	Article	IF	Citations
37	Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD. Frontiers in Neuroscience, 2019, 13, 276.	2.8	7
38	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	8.0	10
39	Spatial intratumor heterogeneity in uveal melanoma: Tumor cell subtypes with a presumed invasive potential exhibit a particular epigenetic staining reaction. Experimental Eye Research, 2019, 182, 175-181.	2.6	18
40	Transcutaneous vagal nerve stimulation improves gastroenteric complaints in Parkinsonâ€™s disease patients. NeuroRehabilitation, 2019, 45, 449-451.	1.3	16
41	Common genetic variants associated with Parkinsonâ€™s disease display widespread signature of epigenetic plasticity. Scientific Reports, 2019, 9, 18464.	3.3	17
42	5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinsonâ€™s disease. Journal of Chemical Neuroanatomy, 2019, 96, 41-48.	2.1	28
43	Basal cell carcinomas developing independently from BAP1â€tumor predisposition syndrome in a patient with bilateral uveal melanoma. Genes Chromosomes and Cancer, 2019, 58, 357-364.	2.8	7
44	Cognitive decline in Parkinsonâ€™s disease: the impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 171-179.	1.9	54
45	A stably self-renewing adult blood-derived induced neural stem cell exhibiting patternability and epigenetic rejuvenation. Nature Communications, 2018, 9, 4047.	12.8	49
46	Lymphatic markers in the human optic nerve: A previous study on podoplanin immunostaining in fetal eyes did not describe lymphatics in the dura mater. Experimental Eye Research, 2018, 176, 266.	2.6	1
47	Polarization and Distribution of Tumor-Associated Macrophages and COX-2 Expression in Basal Cell Carcinoma of the Ocular Adnexae. Current Eye Research, 2018, 43, 1126-1135.	1.5	11
48	BAP1 Immunostaining in Uveal Melanoma: Potentials and Pitfalls. Ocular Oncology and Pathology, 2018, 4, 297-297.	1.0	8
49	DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling. Clinical Epigenetics, 2018, 10, 13.	4.1	39
50	Preâ€•and intraretinal haemorrhages in a 22â€•weekâ€•old fetus of a mother suffering from <scp>HELLP</scp> syndrome and factor V Leiden mutation with deep vein thrombosis. Acta Ophthalmologica, 2017, 95, e83-e84.	1.1	3
51	DNA methylation of imprinted loci of autosomal chromosomes and IGF2 is not affected in Parkinsonâ€™s disease patientsâ€™ peripheral blood mononuclear cells. Neurological Research, 2017, 39, 281-284.	1.3	6
52	Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing Î±-Synuclein. Neurochemical Research, 2017, 42, 1430-1437.	3.3	8
53	Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naÃ¯ve Parkinsonâ€™s disease patients. Genome Medicine, 2017, 9, 39.	8.2	420
54	Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females. Neurobiology of Aging, 2017, 57, 248.e1-248.e5.	3.1	11

#	Article	IF	Citations
55	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. Journal of Neural Transmission, 2017, 124, 1029-1036.	2.8	18
56	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Human Molecular Genetics, 2017, 26, 4028-4041.	2.9	19
57	Sebaceous gland carcinoma of the ocular adnexa â€“ variability in clinical and histological appearance with analysis of immunohistochemical staining patterns. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2277-2285.	1.9	17
58	DNA methylation of DLG4 and GJA-1 of human hippocampus and prefrontal cortex in major depression is unchanged in comparison to healthy individuals. Journal of Clinical Neuroscience, 2017, 43, 261-263.	1.5	9
59	Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinsonâ€™s disease revealed different epigenetic patterns in peripheral blood mononuclear cells. Neurogenetics, 2017, 18, 7-22.	1.4	47
60	Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations. BioMed Research International, 2016, 2016, 1-9.	1.9	24
61	Postural Stability in Parkinsonâ€™s Disease Patients Is Improved after Stochastic Resonance Therapy. Parkinson's Disease, 2016, 2016, 1-7.	1.1	12
62	Stochastic resonance therapy induces increased movement related caudate nucleus activity. Journal of Rehabilitation Medicine, 2016, 48, 815-818.	1.1	9
63	Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e172.	2.2	0
64	Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumabâ€”A Case Report. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, e126-e127.	1.6	36
65	Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2016, 22, e86.	2.2	0
66	Apolipoprotein E Îµ4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
67	Impact of macrophages on tumor growth characteristics in a murine ocular tumor model. Experimental Eye Research, 2016, 151, 9-18.	2.6	4
68	<scp>DNA</scp> methylation in Parkinson's disease. Journal of Neurochemistry, 2016, 139, 108-120.	3.9	78
69	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
70	Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma. Current Eye Research, 2016, 41, 121-128.	1.5	11
71	The Machadoâ€“Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53. PLoS Biology, 2016, 14, e2000733.	5.6	66
72	Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathologica Communications, 2015, 3, 75.	5.2	115

#	Article	IF	Citations
73	PDON: Parkinsonâ€™s disease ontology for representation and modeling of the Parkinsonâ€™s disease knowledge domain. Theoretical Biology and Medical Modelling, 2015, 12, 20.	2.1	29
74	Lâ€dopa increases Î±â€synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. Movement Disorders, 2015, 30, 1794-1801.	3.9	81
75	Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 331-341.	3.2	55
76	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	3.7	90
77	DNA methylation levels of Î±-synuclein intron 1 in the aging brain. Neurobiology of Aging, 2015, 36, 3334.e7-3334.e11.	3.1	23
78	DNA Methylation of the TNF-Î± Promoter Region in Peripheral Blood Monocytes and the Cortex of Human Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2014, 38, 10-15.	1.5	27
79	A Randomized Pilot Study of Stochastic Vibration Therapy in Spinocerebellar Ataxia. Cerebellum, 2014, 13, 237-242.	2.5	30
80	Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinsonâ€™s disease. Neuroscience, 2014, 258, 385-400.	2.3	44
81	Expression of the lymphatic marker podoplanin (D2-40) in human fetal eyes. Experimental Eye Research, 2014, 127, 243-251.	2.6	22
82	Patient Selection for Mechanical Thrombectomy. Clinical Neuroradiology, 2014, 24, 239-244.	1.9	4
83	The relevance of imaging for the diagnosis of Parkinson's disease. Basal Ganglia, 2014, 4, 25-27.	0.3	1
84	Reply to: Cognitive dysfunction in spinocerebellar ataxia type 3: Variable topographies and patterns. Movement Disorders, 2014, 29, 157-158.	3.9	3
85	Progressive cognitive dysfunction in spinocerebellar ataxia type 3. Movement Disorders, 2013, 28, 1435-1438.	3.9	36
86	Cognitive deficits in multiple system atrophy (MSA): Comparison with sporadic adult onset ataxias of unknown aetiology (SAOA) and longitudinal decline. Journal of the Neurological Sciences, 2013, 333, e86.	0.6	0
87	Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Human Molecular Genetics, 2013, 22, 508-518.	2.9	70
88	No association of GBA mutations and multiple system atrophy. European Journal of Neurology, 2013, 20, e61-2.	3.3	28
89	Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Scientific Reports, 2013, 3, 3440.	3.3	383
90	A Possible Genetic Link between MTHFR Genotype and Smoking Behavior. PLoS ONE, 2012, 7, e53322.	2.5	12

#	Article	IF	Citations
91	Mechanical Thrombectomy Compared to Local-Intraarterial Thrombolysis in Carotid T and Middle Cerebral Artery Occlusions. Clinical Neuroradiology, 2012, 22, 141-147.	1.9	35
92	Requirements for Parkinsonâ€™s disease pharmacotherapy from the patientsâ€™ perspective: a questionnaire-based survey. Current Medical Research and Opinion, 2012, 28, 1239-1246.	1.9	15
93	Feasibility of [18F]-2-Fluoro-A85380-PET Imaging of Human Vascular Nicotinic Acetylcholine Receptors In Vivo. JACC: Cardiovascular Imaging, 2012, 5, 528-536.	5.3	28
94	Distinct patterns of cognitive impairment in multiple system atrophy patients of cerebellar and parkinsonian predominance. Basal Ganglia, 2012, 2, 91-96.	0.3	1
95	Extensive Transcriptional Regulation of Chromatin Modifiers during Human Neurodevelopment. PLoS ONE, 2012, 7, e36708.	2.5	23
96	Variants in the 3â€²UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. European Journal of Human Genetics, 2012, 20, 1265-1269.	2.8	19
97	Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics, 2012, 13, 87-91.	1.4	122
98	Excitation-induced ataxin-3 aggregation in neurons from patients with Machadoâ€“Joseph disease. Nature, 2011, 480, 543-546.	27.8	282
99	Stochastic resonance therapy in Parkinson's disease. NeuroRehabilitation, 2011, 28, 353-358.	1.3	33
100	Extracellular phosphorylation of the amyloid Î²-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO Journal, 2011, 30, 2255-2265.	7.8	160
101	FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Human Molecular Genetics, 2011, 20, 2928-2941.	2.9	87
102	Depression in Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 336-338.	3.6	22
103	Spinocerebellar ataxia type 15: diagnostic assessment, frequency, and phenotypic features. Journal of Medical Genetics, 2011, 48, 407-412.	3.2	49
104	Parkinsonâ€™s Disease and Dementia: A Longitudinal Study (DEMPARK). Neuroepidemiology, 2011, 37, 168-176.	2.3	47
105	Transdermal rotigotine for the perioperative management of Parkinsonâ€™s disease. Journal of Neural Transmission, 2010, 117, 855-859.	2.8	64
106	Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) Types 1, 2, 3, and 6. Cerebellum, 2010, 9, 433-442.	2.5	125
107	Depression in Patients with Spinocerebellar Ataxia Type 3 (SCA3). Cerebellum, 2010, 9, 606-607.	2.5	1
108	Callosal tissue loss in multiple system atrophyâ€”A oneâ€year followâ€up study. Movement Disorders, 2010, 25, 2613-2620.	3.9	24

#	Article	IF	Citations
109	Olfactory fMRI in Patients with Parkinson's Disease. Frontiers in Integrative Neuroscience, 2010, 4, 125.	2.1	50
110	Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains. Journal of Neuroscience, 2010, 30, 6355-6359.	3.6	364
111	Nuclear Aggregation of Polyglutamine-expanded Ataxin-3. Journal of Biological Chemistry, 2010, 285, 6532-6537.	3.4	32
112	Tremor in Parkinsonâ€™s disease is not associated with the DRD3 Ser9Gly polymorphism. Parkinsonism and Related Disorders, 2010, 16, 381-383.	2.2	8
113	PGC-1 Î±, A Potential Therapeutic Target for Early Intervention in Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 52ra73.	12.4	691
114	Spinocerebellar ataxia type 11 (SCA11) is an uncommon cause of dominant ataxia among French and German kindreds. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1229-1232.	1.9	47
115	CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Human Molecular Genetics, 2009, 18, 3334-3343.	2.9	88
116	SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5.3	257
117	Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Movement Disorders, 2009, 24, 1080-1084.	3.9	26
118	Parkinsonâ€™s disease influences the perioperative risk profile in surgery. Langenbeck's Archives of Surgery, 2009, 394, 511-515.	1.9	41
119	In vivo voxel-based relaxometry in amyotrophic lateral sclerosis. Journal of Neurology, 2009, 256, 28-34.	3.6	18
120	The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiology of Aging, 2009, 30, 731-738.	3.1	108
121	Bellâ€™s palsy. Journal of Neurology, 2008, 255, 1726-1730.	3.6	49
122	Genes associated with Parkinson syndrome. Journal of Neurology, 2008, 255, 8-17.	3.6	78
123	The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Movement Disorders, 2008, 23, 599-602.	3.9	61
124	Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiology of Disease, 2008, 32, 521-527.	4.4	92
125	Smoking upregulates Î±4Î²2* nicotinic acetylcholine receptors in the human brain. Neuroscience Letters, 2008, 430, 34-37.	2.1	64
126	Inhibition of Thioredoxin reductase induces apoptosis in neuronal cell lines: Role of glutathione and the MKK4/JNK pathway. Biochemical and Biophysical Research Communications, 2007, 359, 759-764.	2.1	34

#	Article	IF	Citations
127	Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochemical and Biophysical Research Communications, 2007, 362, 734-739.	2.1	133
128	Voxel-based morphometry and voxel-based relaxometry in multiple system atrophyâ€"A comparison between clinical subtypes and correlations with clinical parameters. NeuroImage, 2007, 36, 1086-1095.	4.2	103
129	Data protection in biomaterial banks for Parkinson's disease research: The model of GEPARD (Gene bank Parkinson's Disease Germany). Movement Disorders, 2007, 22, 611-618.	3.9	16
130	Bright light therapy in Parkinson's disease: A pilot study. Movement Disorders, 2007, 22, 1495-1498.	3.9	137
131	Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing. European Journal of Neurology, 2007, 14, 1405-1408.	3.3	74
132	Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinsonâ€™s disease. Journal of Neural Transmission, 2007, 114, 1161-1165.	2.8	48
133	Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Experimental Neurology, 2006, 199, 465-478.	4.1	43
134	Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3. Experimental Neurology, 2006, 201, 182-192.	4.1	17
135	An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO Journal, 2006, 25, 1547-1558.	7.8	142
136	Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiology of Disease, 2006, 23, 725-730.	4.4	55
137	Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study. Movement Disorders, 2006, 21, 543-548.	3.9	126
138	TheADH1C stop mutation in multiple system atrophy patients and healthy probands in the United Kingdom and Germany. Movement Disorders, 2006, 21, 2034-2034.	3.9	6
139	Ataxin-3 Represses Transcription via Chromatin Binding, Interaction with Histone Deacetylase 3, and Histone Deacetylation. Journal of Neuroscience, 2006, 26, 11474-11486.	3.6	144
140	Rapamycin alleviates toxicity of different aggregate-prone proteins. Human Molecular Genetics, 2006, 15, 433-442.	2.9	618
141	Unusual Idiopathic Lipid Keratopathy: A Newly Recognized Entity?. JAMA Ophthalmology, 2005, 123, 1435.	2.4	12
142	Multiple regions of Î±-synuclein are associated with Parkinson's disease. Annals of Neurology, 2005, 57, 535-541.	5.3	223
143	Putamen dopamine transporter and glucose metabolism are reduced in SCA17. Annals of Neurology, 2005, 58, 490-491.	5.3	39
144	New mutations in protein kinase CÎ³ associated with spinocerebellar ataxia type 14. Annals of Neurology, 2005, 58, 720-729.	5.3	85

#	Article	IF	Citations
145	Methylenetetrahydrofolate reductase in Parkinson's disease. Annals of Neurology, 2005, 58, 972-973.	5.3	23
146	Alphaâ€synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. Movement Disorders, 2005, 20, 1191-1194.	3.9	67
147	UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. Movement Disorders, 2005, 20, 1338-1343.	3.9	17
148	A Rare Truncating Mutation in ADH1C (G78Stop) Shows Significant Association With Parkinson Disease in a Large International Sample. Archives of Neurology, 2005, 62, 74.	4.5	57
149	Dopamine Transporter Positron Emission Tomography in Spinocerebellar Ataxias Type 1, 2, 3, and 6. Archives of Neurology, 2005, 62, 1280.	4.5	89
150	Probable multiple system atrophy in a German family. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 924-925.	1.9	64
151	Structural and functional analysis of ataxin-2 and ataxin-3. FEBS Journal, 2004, 271, 3155-3170.	0.2	118
152	Lack of genetic dispositions to hyperhomocysteinemia in Alzheimer disease. , 2004, 131A, 101-102.		22
153	Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Movement Disorders, 2004, 19, 705-707.	3.9	40
154	Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Applied Radiation and Isotopes, 2004, 61, 1235-1240.	1.5	31
155	Inflammation in Parkinson's disease. Journal of Neurology, 2003, 250, i35-i38.	3.6	35
156	Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. Free Radical Biology and Medicine, 2003, 34, 1517-1530.	2.9	15
157	Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Movement Disorders, 2003, 18, 659-667.	3.9	255
158	The human MJD gene: genomic structure and functional characterization of the promoter region. Gene, 2003, 314, 81-88.	2.2	18
159	Gene Expression Profiling in Ataxin-3 Expressing Cell Lines Reveals Distinct Effects of Normal and Mutant Ataxin-3. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1006-1018.	1.7	72
160	Genes implicated in the pathogenesis of spinocerebellar ataxias. Drugs of Today, 2003, 39, 927.	2.4	7
161	Genes implicated in the pathogenesis of spinocerebellar ataxias. Drugs of Today, 2003, 39, 927-37.	1.1	1
162	Structural modeling of ataxin-3 reveals distant homology to adaptins. Proteins: Structure, Function and Bioinformatics, 2002, 50, 355-370.	2.6	31

#	Article	IF	Citations
163	Inflammatory Genes Are Upregulated in Expanded Ataxin-3-Expressing Cell Lines and Spinocerebellar Ataxia Type 3 Brains. Journal of Neuroscience, 2001, 21, 5389-5396.	3.6	110
164	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	3.9	6
165	Is age-related macular degeneration associated with pinguecula or scleral plaque formation?. Current Eye Research, 2001, 23, 33-37.	1.5	8
166	Altered expression of calcium- and apoptosis-regulating proteins in multiple system atrophy purkinje cells. Movement Disorders, 2000, 15, 269-275.	3.9	19
167	The molecular biology of the autosomal-dominant cerebellar ataxias. Movement Disorders, 2000, 15, 604-612.	3.9	49
168	Bilateral necrotizing scleritis and blindness in the myelodysplastic syndrome presumably due to relapsing polychondritis. Acta Ophthalmologica, 2000, 78, 228-231.	0.3	13
169	Flupirtine and retigabine prevent l-glutamate toxicity in rat pheochromocytoma PC 12 cells. European Journal of Pharmacology, 2000, 400, 155-166.	3.5	32
170	Cell death in polyglutamine diseases. Cell and Tissue Research, 2000, 301, 189-204.	2.9	66
171	Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochemistry International, 2000, 36, 489-497.	3.8	41
172	High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Human Molecular Genetics, 1999, 8, 1169-1176.	2.9	69
173	Cell death and apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathologica, 1999, 97, 408-412.	7.7	92
174	Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. Journal of Neuroimmunology, 1999, 100, 156-168.	2.3	146
175	Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Research, 1999, 826, 53-62.	2.2	166
176	Differential effects of l-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neuroscience Letters, 1999, 264, 1-4.	2.1	69
177	MPP+ Inhibits Proliferation of PC12 Cells by a p21WAF1/Cip1-Dependent Pathway and Induces Cell Death in Cells Lacking p21WAF1/Cip1. Experimental Cell Research, 1999, 250, 75-85.	2.6	50
178	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857.	11.2	93
179	Bcl-2, Bax and Bcl-x expression in neuronal apoptosis: a study of mutant weaver and lurcher mice. Acta Neuropathologica, 1998, 96, 233-238.	7.7	27
180	Potentiation of Treosulfan Toxicity by the Glutathione-Depleting Agent Buthionine Sulfoximine in Human Malignant Glioma Cells. Biochemical Pharmacology, 1998, 55, 349-359.	4.4	27

#	Article	IF	Citations
181	Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94.	3.9	186
182	Mechanisms of cell death in cerebellar disorders. Restorative Neurology and Neuroscience, 1998, 13, 69-73.	0.7	1
183	Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: The effects of 3-acetylpyridine neurotoxicity. Neuroscience, 1997, 81, 721-734.	2.3	28
184	Cooperative Interception of Neuronal Apoptosis by BCLâ€2 and BAGâ€1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species. Journal of Neurochemistry, 1997, 69, 2075-2086.	3.9	94
185	Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. NeuroReport, 1996, 7, 921-923.	1.2	149
186	New medical and surgical treatments for ParkinsonÊ¼s disease. Current Opinion in Neurology, 1994, 7, 346-352.	3.6	20
187	The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 1992, 31, 713-715.	4.1	39
188	GABAB receptors and spasticity. Trends in Pharmacological Sciences, 1990, 11, 103.	8.7	8
189	Phaclofen antagonizes the depressant effect of baclofen on spinal reflex transmission in rats. Brain Research, 1989, 496, 341-344.	2.2	14
190	?-Aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system. Experimental Brain Research, 1988, 70, 618-26.	1.5	29